Xia Gu1, Jingbo Hou, Shuang Yang, Huai Yu, Jinwei Tian, Fang Liu, Ning Li, Bo Yu, Ik-Kyung Jang. 1. aDepartment of Cardiology, Second Affiliated Hospital of Harbin Medical University bThe Key Laboratories of Myocardial Ischemia, Chinese Ministry of Education, Harbin, People's Republic of China cCardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Abstract
BACKGROUND: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a specific biomarker specific for vascular inflammation. Inflammation has a significant association with plaque progression. The fibrous-cap thickness (FCT) is one of the major determinants of plaque vulnerability in atherosclerotic plaques. However, data on the relationship between Lp-PLA2 activity and FCT in lipid plaque are limited. This study aimed to evaluate the in-vivo association between changes in Lp-PLA2 activity and FCT and plaque volume in patients with acute coronary syndrome (ACS). PATIENTS AND METHODS: Twenty-four consecutive patients with ACS were enrolled between May 2010 and May 2012. The plaque volume and FCT of nonculprit lipid-rich plaques were assessed by intravascular ultrasound and optical coherence tomography, respectively, at baseline and after 12 months. Lp-PLA2 activity was determined using the colorimetric assay kit. RESULTS: During the 12 months of observation, FCT increased significantly from baseline to follow-up, with a mean percent change of 74.4±46.8%. A significant correlation was observed between changes in Lp-PLA2 activity and changes in FCT (r=-0.56, P=0.006). Changes in plaque volume were also correlated significantly with changes in Lp-PLA2 activity during the study period (r=0.52, P=0.01). CONCLUSION: Significant associations between serial changes in Lp-PLA2 activity and changes in FCT and plaque volume were observed in patients with ACS.
BACKGROUND:Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a specific biomarker specific for vascular inflammation. Inflammation has a significant association with plaque progression. The fibrous-cap thickness (FCT) is one of the major determinants of plaque vulnerability in atherosclerotic plaques. However, data on the relationship between Lp-PLA2 activity and FCT in lipid plaque are limited. This study aimed to evaluate the in-vivo association between changes in Lp-PLA2 activity and FCT and plaque volume in patients with acute coronary syndrome (ACS). PATIENTS AND METHODS: Twenty-four consecutive patients with ACS were enrolled between May 2010 and May 2012. The plaque volume and FCT of nonculprit lipid-rich plaques were assessed by intravascular ultrasound and optical coherence tomography, respectively, at baseline and after 12 months. Lp-PLA2 activity was determined using the colorimetric assay kit. RESULTS: During the 12 months of observation, FCT increased significantly from baseline to follow-up, with a mean percent change of 74.4±46.8%. A significant correlation was observed between changes in Lp-PLA2 activity and changes in FCT (r=-0.56, P=0.006). Changes in plaque volume were also correlated significantly with changes in Lp-PLA2 activity during the study period (r=0.52, P=0.01). CONCLUSION: Significant associations between serial changes in Lp-PLA2 activity and changes in FCT and plaque volume were observed in patients with ACS.